Invention Grant
- Patent Title: Tumor vaccination involving a humoral immune response against self-proteins
-
Application No.: US15341528Application Date: 2016-11-02
-
Publication No.: US10526387B2Publication Date: 2020-01-07
- Inventor: Thorsten Klamp , Ugur Sahin , Ozlem Tureci , Michael Koslowski , Thomas Hiller , Jens Schumacher
- Applicant: BioNTech AG
- Applicant Address: DE Mainz DE Mainz
- Assignee: BIONTECH PROTEIN THERAPEUTICS GMBH,TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVRESITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
- Current Assignee: BIONTECH PROTEIN THERAPEUTICS GMBH,TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVRESITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
- Current Assignee Address: DE Mainz DE Mainz
- Agency: Neal, Gerber & Eisenberg LLP
- Agent Kevin A. O'Connor
- Priority: EP10002775 20100316; EP10016216 20101230
- Main IPC: C07K14/47
- IPC: C07K14/47 ; A61K39/00 ; C07K14/005 ; C12N7/00

Abstract:
The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.
Public/Granted literature
- US20170072035A1 TUMOR VACCINATION INVOLVING A HUMORAL IMMUNE RESPONSE AGAINST SELF-PROTEINS Public/Granted day:2017-03-16
Information query